The agency said it had received adverse event reports after people used compounded versions of the drug
These GLP-1 and dual GIP/GLP-1 receptor agonists work by reducing appetite, slowing digestion, and improving metabolic function
These symptoms typically emerge during dose escalation and often diminish over several weeks as tolerance develops
Last reviewed: June 5, 2026 Last updated: June 5, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Discard the pen Because theres a needle at the end of the injector pen, the pen should be thrown away in a dedicated sharps container
Read more Whether or not Blue Cross Blue Shield covers Wegovy, there's a path that skips insurance Across the 33+ Blue plans, weight-loss GLP-1 coverage is increasingly restricted